Literature DB >> 1847594

Glucocorticoids induce neutral endopeptidase in transformed human tracheal epithelial cells.

D B Borson1, D C Gruenert.   

Abstract

Neutral endopeptidase (NEP, also known as enkephalinase, CALLA, or EC 3.4.24.11) is a membrane-bound peptidase present in many different cell types. Previous studies have shown that it modulates the actions of a variety of biologically active peptides on several airway responses. More recent studies have demonstrated that reductions in neutral endopeptidase activity in animal airways is associated with increased responses to exogenously applied and endogenously released peptides. To study the regulation of NEP expression, we used human airway epithelial cells transformed in vitro with an origin-defective SV40 plasmid. Enzymatic activity, measured using [3H-Tyr,D-Ala2]leucine enkephalin, increased with cell density (1.4 ng/10(6) cells at 530 cells/cm2 and 21 ng/10(6) cells at confluence, 400 X 10(3) cells/cm2). In both confluent and nonconfluent cultures, the glucocorticoid budesonide increased neutral endopeptidase activity in time- and concentration-dependent fashions. Maximal increases of 10 ng/10(6) cells greater than control were observed after 6 days of incubation at 10(-7) M budesonide. Dexamethasone also increased NEP, suggesting that the effect is due to glucocorticoid receptor effects. Transcription, as assessed by Northern blot analysis of total cellular RNA, showed that NEP-specific RNAs also increased with increasing concentration of glucocorticoid. We conclude that neutral endopeptidase can be increased by cell growth or density and by glucocorticoids and that the effects of glucocorticoids are mediated by increased NEP gene expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847594     DOI: 10.1152/ajplung.1991.260.2.L83

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.

Authors:  M A Shipp; G E Tarr; C Y Chen; S N Switzer; L B Hersh; H Stein; M E Sunday; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 2.  An overview of glucocorticoid anti-inflammatory actions.

Authors:  R P Schleimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Neutral endopeptidase and kininase II mediate glucocorticoid inhibition of neurogenic inflammation in the rat trachea.

Authors:  G Piedimonte; D M McDonald; J A Nadel
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides.

Authors:  J M Bathon; D Proud; S Mizutani; P E Ward
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

5.  Attenuation of bradykinin-induced mucosal inflammation by topical budesonide in rat trachea.

Authors:  R Brattsand; S R O'Donnell; A Miller-Larsson; K L Rauchle
Journal:  Agents Actions       Date:  1991-09

6.  [Migraine recurrence due to intracranial metastasis of a thyroid carcinoma].

Authors:  C J Schankin; J Wagner; M Elstner; V M Reinisch; A Straube
Journal:  Nervenarzt       Date:  2008-04       Impact factor: 1.214

7.  Upregulation of neurokinin-1 receptor expression in the lungs of patients with sarcoidosis.

Authors:  Terence M O'Connor; Joseph O'Connell; Darren I O'Brien; Michael W Bennett; Triona Goode; Louise Burke; Charles P Bredin; Fergus Shanahan
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

8.  Dexamethasone reduces tachykinin but not ACh airway hyperreactivity after O3.

Authors:  C G Murlas; Z Lang; V Chodimella
Journal:  Lung       Date:  1993       Impact factor: 2.584

9.  Dexamethasone increases airway epithelial cell neutral endopeptidase by enhancing transcription and new protein synthesis.

Authors:  Z Lang; C G Murlas
Journal:  Lung       Date:  1993       Impact factor: 2.584

Review 10.  Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19.

Authors:  Joshua R Cook; John Ausiello
Journal:  Rev Endocr Metab Disord       Date:  2021-07-01       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.